Clinical Trials Logo

Burkitt Lymphoma (BL)) clinical trials

View clinical trials related to Burkitt Lymphoma (BL)).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02983097 Terminated - Clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

R²-DHAP
Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide, an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP. R-DHAP consists of a monoclonal antibody called Rituximab and chemotherapy consisting of Dexamethasone, high dose Cytarabine, often called Ara-C, and platinum based chemotherapy, either cisplatinum, or, if treatment with cisplatinum is contraindicated, carboplatinum.